• All
  • Financials
  • Insiders
Webull provides the latest Rubius Therapeutics (RUBY) stock and general news. This information may help you make smarter investment decisions.
About RUBY
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.